Corneal angiogenesis and lymphangiogenesis

Wu, Chun Ying; Ellenberg, David; Chang, Jin Hong

doi:10.1016/b978-0-7020-2983-7.00010-3

Cited by 4 publications

(2 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both pannus or stromal neovascularization is regulated by the balance between vascular endothelial growth factors such as VEGF, VEGF-C, VEGF-D, sFlt, VEGFR3, endostatin, and thrombospondin-1 and -2 within the cornea and therefore are the prime targets for their modulation using GT (Table 3). 27 …”

Section: Gene Therapy Strategiesmentioning

confidence: 99%

“…26 Both pannus or stromal neovascularization is regulated by the balance between vascular endothelial growth factors such as VEGF, VEGF-C, VEGF-D, sFlt, VEGFR3, endostatin, and thrombospondin-1 and -2 within the cornea and therefore are the prime targets for their modulation using GT (Table 3). 27 In Vivo Corneal Gene Therapy for Corneal Haze, Clouding, Wound Healing Further attempts using in vivo corneal GT were made for the therapeutic purpose of corneal haze, opacity, corneal clouding management of mucopolysaccharidosis VII, wound healing (Table 3). 28,29 Retro viral-mediated delivery of dominant-negative mutant cyclin G1 (dnG1) prevented the development of corneal haze after phototherapeutic keratectomy (PTK) in rabbits.…”

Section: In Vivo Corneal Gene Therapymentioning

confidence: 99%

See 1 more Smart Citation

New Frontier in the Management of Corneal Dystrophies: Basics, Development, and Challenges in Corneal Gene Therapy and Gene Editing

Salman

Verma

Singh

et al. 2022

Asia-Pacific Journal of Ophthalmology

View full text Add to dashboard Cite

: Corneal dystrophies represent a group of heterogeneous hereditary disorders causing progressive corneal opacification and blindness. Current corneal transplant management for corneal dystrophies faces the challenges of repeated treatments, complex surgical procedures, shortage of appropriate donor cornea, and, more importantly, graft rejection. Genetic medicine could be an alternative treatment regime to overcome such challenges. Cornea carries promising scope for a gene-based therapy involving gene supplementation, gene silencing, and gene editing in both ex vivo and in vivo platforms. In the cornea, ex vivo gene therapeutic strategies were attempted for corneal graft survival, and in vivo gene augmentation therapies aimed to prevent herpes stromal keratitis, neovascularization, corneal clouding, and wound healing. However, none of these studies followed a clinical trial–based successful outcome. CRISPR/Cas system offers a broad scope of gene editing and engineering to correct underlying genetic causes in corneal dystrophies. Corneal tissue--specific gene correction in vitro with minimal off-target effects and optimal gene correction efficiency followed by their successful surgical implantation, or in vivo CRISPR administration targeting pathogenic genes finds a way to explore therapeutic intervention for corneal dystrophies. However, there are many limitations associated with such CRISPR-based corneal treatment management. This review will look into the development of corneal gene therapy and CRISPR-based study in corneal dystrophies, associated challenges, potential approaches, and future directions.

show abstract

Section: Gene Therapy Strategiesmentioning

confidence: 99%